Friday, 16 October 2026
Friday, 16 October 2026
- In brief
- 1Pig kidneys stored like glass at -150C, one for over a year, are rewarmed and work again, scientists report
- 2Ebola reaches an eighth province of Congo
- 3Ebola kills most children at one Congo centre
- 4US plan would let pharmacies make untested peptides
- 5US regulator warns of bursting heart valve tool
- 6$700 million of Ebola money cannot be traced
- 7Europe's worst West Nile season on record
- 8First trial of a vaccine for Congo's Ebola strain
- 9GSK may cut 1,217 jobs in Belgium
- 10Vanda's social anxiety pill fails its final test
- 11Osivax flu vaccine misses its goal
- 12South Africa's drug firms ask for arrests over fake jabs
- 134 in 10 US high school students binge eat
- 14A same-day test finds hidden infections in sick children
- 15One brain shows what clearing amyloid may do
- 16AstraZeneca pays an AI firm to find drug targets
- 17Merck and Moderna choose where their cancer vaccine goes next
- 18US prosecutors offer a deal to firms that report fraud
- 19OrbiMed raises $3 billion, a third for Asia
- 20OMass raises $310 million in Oxford
- 21Galapagos's cell therapies sold to its ex-chief's start-up
- 22How an Alzheimer's gene may strip nerve coating
- 23Eating late linked to liver disease
- 24Northern Ireland's hospital doctors to strike
- 25MPs find endometriosis costs women their jobs
- 26A US lawmaker wants faster early drug trials
16 Oct · Biotech · In brief
Biotech · Friday, 16 October 2026
Biotech, in brief
26 stories · 29 sources
Swipe up for the day in brief ↑Scroll down for the day in brief ↓
What is moving · 1 of 4
Ebola outrunning the response
Ebola has reached North Ubangi, an eighth province of Congo, on the border with the Central African Republic.
What is moving · 2 of 4
Untested medicines sold openly
The US health department sent the US president's budget office a plan to let pharmacies make peptide injections that the FDA has called too risky.
What is moving · 3 of 4
Drugs failing bigger tests
Vanda's social anxiety pill did no better than a dummy pill in 546 adults, after a smaller trial had looked good in women.
What is moving · 4 of 4
Money for young drug firms
OrbiMed, a big health investor, raised $3 billion, with over $1 billion of it for Asia.
26 stories
10 sources
Biotech, in brief
- 2Ebola outbreak in DR Congo spreads to new province bordering CAR
- 3WHO raises alarm over undetected Ebola cases in DR Congo
- 6Africa CDC probes missing millions meant for Ebola response
- 7Trump administration advances plan for peptide drugs favored by RFK Jr.
- 9AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
- 10Vanda pauses social anxiety program after ex-Novartis asset flunks phase 3 study
- 11Osivax focuses on combo strategy for flu vaccine after phase 2 fail
- 14OrbiMed's largest-ever Asian fund contributes to $3B war chest
- 15Why OMass' $310M series C marks 'fantastic milestone' on journey to become 'Britain's Big Biotech'
- 26Crackdown on illegal weight loss drugs
Pig kidneys stored like glass at -150C, one for over a year, are rewarmed and work again, scientists report
Swipe up for the story ↑Scroll down for the story ↓
Scientists at the University of Minnesota cooled pig kidneys to -150C, turning them into a glass-like solid, and stored them for days, weeks or months.
Who is involved
Erik Finger
a transplant surgeon at the University of Minnesota; he co-led the work
Who is involved
John Bischof
a bioengineer at the University of Minnesota; he worked with Finger on the freezing and warming method
Why it matters
Watch whether rewarmed kidneys keep pigs alive for weeks rather than hours, and whether the team's first tests with human kidneys show less injury.
Nobody knows yet
Whether the frozen pig kidneys would keep an animal alive.
They were watched inside pigs for only two hours, and Greg Fahy says the tests cannot show it.
Nobody knows yet
Whether human kidneys can be frozen and rewarmed the same way.
The team has not tried yet, and the antifreeze chemicals injured the pig kidneys.
Good news
Pig kidneys kept frozen for just over a year were rewarmed at the University of Minnesota and made urine again. Today a donated human kidney must be used within 24 to 36 hours.
The short version
That's the story in short.
The whole story has 12 more parts.
or swipe up for the next storyor scroll on for the next story ↓
The whole story, in 12 parts ↓
Part 1 of 12 · Who else is involved
Greg Fahy
a cryobiologist, a scientist who studies living things at very low temperatures; he was not involved and worries about the damage
Part 1 of 12 · Who else is involved
Kevin Myer
head of LifeGift, a Texas group that collects donated organs; he called a year of storage a very big deal
Part 2 of 12
One kidney stayed in the freezer for just over a year.
Part 2 of 12
After rewarming, it made urine at once on a machine that pumps fluid through it.
Part 3 of 12
Today a donated human kidney must reach its patient within 24 to 36 hours.
Part 4 of 12
Freezing an organ normally grows ice crystals that damage it.
Part 4 of 12
The team first fills the kidney with antifreeze chemicals, so it sets like glass instead of ice.
Part 5 of 12
Warming a big organ evenly all the way through is just as hard.
Part 5 of 12
The team pumps tiny iron particles through the kidney, then heats them all at once with a magnetic field.
Part 6 of 12
A pig kidney weighs about 100 grams, a rat kidney about one.
Part 6 of 12
The same team did this with rat kidneys kept up to 100 days, in work published in 2023.
Part 7 of 12
Rewarmed kidneys were put into pigs and watched for two hours.
Part 7 of 12
They turned pink and began making urine within about a minute.
Part 8 of 12
They made only about two-thirds of the normal amount of urine and showed injury.
Part 8 of 12
The researchers blame the antifreeze chemicals.
Part 9 of 12
The work is a preprint, posted online before other scientists have checked it.
Part 10 of 12
Greg Fahy, a pioneer of organ freezing, says these tests cannot show whether the kidneys would have kept an animal alive.
Part 11 of 12
Organ banks would give doctors more time to match organs to patients, and possibly to prepare a patient's immune system before surgery.
Part 12 of 12
Next the team plans longer tests in pigs and its first experiments with human kidneys.
1 source
Pig kidneys stored like glass at -150C, one for over a year, are rewarmed and work again, scientists report
The full story
Pig kidneys stored like glass at -150C, one for over a year, are rewarmed and work again, scientists report
Scientists at the University of Minnesota cooled pig kidneys to -150C, turning them into a glass-like solid, and stored them for days, weeks or months.
One kidney stayed in the freezer for just over a year.
Today a donated human kidney must reach its patient within 24 to 36 hours.
Freezing an organ normally grows ice crystals that damage it.
Warming a big organ evenly all the way through is just as hard.
A pig kidney weighs about 100 grams, a rat kidney about one.
Rewarmed kidneys were put into pigs and watched for two hours.
They made only about two-thirds of the normal amount of urine and showed injury.
The work is a preprint, posted online before other scientists have checked it.
Greg Fahy, a pioneer of organ freezing, says these tests cannot show whether the kidneys would have kept an animal alive.
Organ banks would give doctors more time to match organs to patients, and possibly to prepare a patient's immune system before surgery.
Next the team plans longer tests in pigs and its first experiments with human kidneys.
Why it matters. Watch whether rewarmed kidneys keep pigs alive for weeks rather than hours, and whether the team's first tests with human kidneys show less injury.
Ebola reaches an eighth province of Congo
Swipe up for the story ↑Scroll down for the story ↓
Two Ebola cases have been found in North Ubangi, a province of Congo on its border with the Central African Republic, two health officials told Reuters on Thursday.
Congo's government had not yet announced it.
Ituri, the worst-hit province, alone has 6,734 cases and 3,177 deaths.
Why it matters
The WHO says about a third of new cases are found only after the person has died outside a clinic, so they were never isolated.
Why it matters
North Ubangi lies on the border with the Central African Republic, so the virus now sits at another country's edge.
Nobody knows yet
How far Ebola has really spread in Congo.
About a third of new cases are found only after the person has died, and Congo had not announced the North Ubangi cases when officials told Reuters.
3 sources
Ebola reaches an eighth province of Congo
The full story
Ebola reaches an eighth province of Congo
Two Ebola cases have been found in North Ubangi, a province of Congo on its border with the Central African Republic, two health officials told Reuters on Thursday.
Why it matters. The WHO says about a third of new cases are found only after the person has died outside a clinic, so they were never isolated.
Ebola kills most children at one Congo centre
Swipe up for the story ↑Scroll down for the story ↓
Medecins Sans Frontieres (MSF), the medical charity, says children are being hit hard by Congo's Ebola outbreak.
24 of 30
children who died at MSF's Butembo centre, June to September
At its treatment centre in Butembo, in North Kivu province, 24 of 30 children died between June and September, most of them under five.
In North Kivu, children under five make up 24% of confirmed cases.
Why it matters
Children are usually left out of vaccine and drug trials until adults have been tested, MSF says, so they wait longest for new tools.
Why it matters
Doctors also lack guidance on safe doses of experimental medicines for children.
Who pays
Young children in North Kivu
24 of 30 children treated at one Butembo centre died, and children are left out of most Ebola vaccine trials.
Nobody knows yet
Why so many young children died at MSF's Butembo centre.
MSF thinks many caught Ebola inside clinics treating them for other illnesses, but that is its judgement from its own cases, not a finished study.
1 source
Ebola kills most children at one Congo centre
The full story
Ebola kills most children at one Congo centre
Medecins Sans Frontieres (MSF), the medical charity, says children are being hit hard by Congo's Ebola outbreak.
24 of 30
children who died at MSF's Butembo centre, June to September
Why it matters. Children are usually left out of vaccine and drug trials until adults have been tested, MSF says, so they wait longest for new tools.
US plan would let pharmacies make untested peptides
Swipe up for the story ↑Scroll down for the story ↓
A US government website showed on Thursday that the US health department, led by Robert F.
Kennedy Jr., had sent a peptides 'interim access policy' to the US president's budget office for review.
Peptides are short chains of protein building blocks, injected by some people to build muscle or look younger; most evidence on them is from animals.
Two people familiar with the plan say pharmacies would be told they will not be targeted for making some, including BPC-157.
The FDA had put BPC-157 on its list of substances too risky for pharmacies to make.
Why it matters
The FDA names contamination, allergic reactions and tumour growth among the possible risks.
Why it matters
Hims & Hers and Noom, two online health companies, say they will sell peptides if the US government eases access.
What's really going on
The US health department plans to let pharmacies make peptide injections such as BPC-157 by promising not to act against them, while the FDA's list still calls them too risky.
Who gains
Sellers of peptide injections
If pharmacies may make them, clinics and online firms such as Hims & Hers and Noom can sell them openly, in a market analysts put at $2 billion to $3 billion.
Who pays
People who inject untested peptides
The FDA lists contamination, allergic reactions and tumour growth as possible risks, and most of the evidence is from animals.
Nobody knows yet
What exactly the US peptides plan allows.
The filing to the US president's budget office gives no details, and what is known comes from two people who spoke without being named.
1 source
US plan would let pharmacies make untested peptides
The full story
US plan would let pharmacies make untested peptides
A US government website showed on Thursday that the US health department, led by Robert F. Kennedy Jr., had sent a peptides 'interim access policy' to the US president's budget office for review.
Why it matters. The FDA names contamination, allergic reactions and tumour growth among the possible risks.
US regulator warns of bursting heart valve tool
Swipe up for the story ↑Scroll down for the story ↓
The FDA, the US drug and medical device regulator, warned on Thursday of a possibly high-risk problem with some Edwards Lifesciences delivery systems.
The tools place a new mitral heart valve through a thin tube in a blood vessel, instead of open-heart surgery.
Edwards received three reports of the tool's balloon bursting while being inflated, linked to one death and one serious injury.
The company has asked hospitals to stop using affected devices and send them back.
Why it matters
A burst balloon can block blood vessels or trap the device, which may force surgery on patients usually judged too frail for it.
Why it matters
The valve system, SAPIEN M3, was approved in the US only in December 2025.
Who pays
Patients given Edwards' new mitral valve
A bursting balloon on the tool has been linked to one death and one serious injury, in people usually too frail for open surgery.
Nobody knows yet
How many Edwards valve tools are affected, and where.
The FDA warning reported by Reuters names the product but gives no count of devices or hospitals.
1 source
US regulator warns of bursting heart valve tool
The full story
US regulator warns of bursting heart valve tool
The FDA, the US drug and medical device regulator, warned on Thursday of a possibly high-risk problem with some Edwards Lifesciences delivery systems.
Why it matters. A burst balloon can block blood vessels or trap the device, which may force surgery on patients usually judged too frail for it.
$700 million of Ebola money cannot be traced
Swipe up for the story ↑Scroll down for the story ↓
Africa CDC, the African Union's public health agency, says it cannot trace more than $700 million meant for Congo's Ebola response.
Donors say they paid $962 million to the groups running the response.
A check with Congo's health authorities could follow only slightly more than $200 million to the work on the ground.
- Traced to the response$200m · 21%
- Not traced$762m · 79%
Fewer than 30% of those groups came to account for the money, its head, Jean Kaseya, said on 14 October.
Why it matters
The money that cannot be found is more than three times the money that can, in an outbreak that is still spreading.
Why it matters
Congo has fought many epidemics, and worries about tracking aid money there are not new.
How it works
Why a banned medicine can be sold without the ban being lifted
How it works
A ban only bites when someone checks and punishes, so a government can let a product be sold just by promising not to act.
How it works · step 1 of 5
A government list says a product is too risky to make or sell
How it works · step 2 of 5
The list only bites when someone checks and punishes
How it works · step 3 of 5
Changing the list takes years of public steps
How it works · step 4 of 5
Promising not to punish takes one decision
How it works · step 5 of 5
Sellers act on the promise, and the list stays as it was
The twist
In the US, BPC-157 could stay on the FDA's too-risky list and still be made by pharmacies, if the US government simply says it will not act against them.
The picture
The plan, as two people familiar with it describe it, leaves BPC-157 on the list and tells pharmacies they will not be targeted for making it.
Seen the same day
The ban on selling them is already written, but cases depend on prosecutors outside the regulator, so sellers advertise in the open.
Seen the same day
The fraud law did not change; what changed is how hard prosecutors hit a firm that reports itself, with a cap on what it pays.
Seen the same day
Groups were meant to account for donors' money, but fewer than 30% came when asked, so the rule went unchecked.
The catch
A promise not to punish is weaker than a changed law: a later government can take it back, and pharmacies that relied on it could be caught out.
The whole
A person buying BPC-157 online sees only a product on sale.
The whole
The FDA's scientists know it is on the too-risky list, the pharmacist knows the US government has promised not to act, and nobody along the way sees all of it.
Who pays
People in Congo's Ebola zones
More than $700 million meant for the response to their outbreak cannot be traced.
Nobody knows yet
Where the untraced $700 million of Ebola money went.
Fewer than 30% of the groups that received it came to account for it.
1 source
$700 million of Ebola money cannot be traced
The full story
$700 million of Ebola money cannot be traced
Africa CDC, the African Union's public health agency, says it cannot trace more than $700 million meant for Congo's Ebola response.
- Traced to the response$200m · 21%
- Not traced$762m · 79%
Why it matters. The money that cannot be found is more than three times the money that can, in an outbreak that is still spreading.
Europe's worst West Nile season on record
Swipe up for the story ↑Scroll down for the story ↓
Europe has had its worst West Nile virus season on record, the ECDC, the EU's disease agency, said on Thursday.
EU countries reported 1,715 human cases caught locally and 130 deaths, as of 7 October.
Belgium recorded 15 cases, its first ever caught inside the country, and the Netherlands 59.
Why it matters
The ECDC expects the virus to keep moving north in the coming years, and there is no vaccine for people.
1 source
Europe's worst West Nile season on record
The full story
Europe's worst West Nile season on record
Europe has had its worst West Nile virus season on record, the ECDC, the EU's disease agency, said on Thursday.
Why it matters. The ECDC expects the virus to keep moving north in the coming years, and there is no vaccine for people.
First trial of a vaccine for Congo's Ebola strain
Swipe up for the story ↑Scroll down for the story ↓
Scientists in Masaka, a city in southern Uganda, have started a small first trial of a vaccine against the Bundibugyo strain of Ebola.
The vaccine was developed at the University of Oxford, and the trial aims to recruit 110 volunteers, each followed for 12 months.
A phase 1 trial checks whether a vaccine is safe and whether the body makes an immune response.
Congo will start a larger trial this month of Ervebo, a vaccine made for a different Ebola strain.
Why it matters
No vaccine exists yet for the strain driving Congo's outbreak, so this is an early step toward one.
Good news
Scientists in Masaka, Uganda, have begun a first safety trial of an Oxford vaccine against the Bundibugyo strain of Ebola, for which no vaccine exists yet.
1 source
First trial of a vaccine for Congo's Ebola strain
The full story
First trial of a vaccine for Congo's Ebola strain
Scientists in Masaka, a city in southern Uganda, have started a small first trial of a vaccine against the Bundibugyo strain of Ebola.
Why it matters. No vaccine exists yet for the strain driving Congo's outbreak, so this is an early step toward one.
GSK may cut 1,217 jobs in Belgium
Swipe up for the story ↑Scroll down for the story ↓
GSK, the British drugmaker, may cut up to 1,217 jobs in Belgium, across research, manufacturing and support staff.
Belgium holds three main sites of GSK's vaccine business, and the company employs about 8,500 people there.
The cuts are part of a plan, announced in July, to save 1.9 billion pounds a year by 2029.
Fierce Biotech, a trade outlet, says one reason is spare capacity in GSK's Belgian vaccine supply chain.
Why it matters
GSK says the savings will go to its most advanced new medicines and vaccines.
Who pays
GSK staff in Belgium
Up to 1,217 jobs may go so GSK can move money to its most advanced new medicines.
1 source
GSK may cut 1,217 jobs in Belgium
The full story
GSK may cut 1,217 jobs in Belgium
GSK, the British drugmaker, may cut up to 1,217 jobs in Belgium, across research, manufacturing and support staff.
Why it matters. GSK says the savings will go to its most advanced new medicines and vaccines.
Vanda's social anxiety pill fails its final test
Swipe up for the story ↑Scroll down for the story ↓
A final-stage trial of Vanda Pharmaceuticals' pill for social anxiety disorder missed its main goal.
In 546 adults, people took one dose of the drug or a dummy pill, then gave a stressful talk to a panel that offered no encouragement.
Women on the drug felt no less distress than women on the dummy pill.
Vanda judged women only because a smaller earlier trial found a benefit in them but not in everyone.
Why it matters
Vistagen, another company, failed two final-stage social anxiety trials, in December and June.
Nobody knows yet
Whether Vanda's drug helps anyone with social anxiety.
Vanda has paused it while it studies the full data, which it has not released.
1 source
Vanda's social anxiety pill fails its final test
The full story
Vanda's social anxiety pill fails its final test
A final-stage trial of Vanda Pharmaceuticals' pill for social anxiety disorder missed its main goal.
Why it matters. Vistagen, another company, failed two final-stage social anxiety trials, in December and June.
Osivax flu vaccine misses its goal
Swipe up for the story ↑Scroll down for the story ↓
Osivax, a French biotech, said on 15 October that its flu vaccine failed a mid-stage trial in 2,850 healthy adults in Europe.
The vaccine, OVX836, protected 24% of people against flu, far below the 50% the trial needed.
It aims at a protein inside the flu virus that changes little from year to year.
Today's flu vaccines aim at proteins on the outside, which change, so they must be remade each season.
Why it matters
Osivax will now test its vaccine mixed with GC Biopharma's ordinary seasonal flu shot, approved in South Korea.
Why it matters
It hopes the mix will widen the protection a yearly flu jab gives.
1 source
Osivax flu vaccine misses its goal
The full story
Osivax flu vaccine misses its goal
Osivax, a French biotech, said on 15 October that its flu vaccine failed a mid-stage trial in 2,850 healthy adults in Europe.
Why it matters. Osivax will now test its vaccine mixed with GC Biopharma's ordinary seasonal flu shot, approved in South Korea.
South Africa's drug firms ask for arrests over fake jabs
Swipe up for the story ↑Scroll down for the story ↓
Drug industry leaders in South Africa called on Wednesday for seizures, arrests and prosecutions over weight-loss products sold without approval.
They singled out products sold as retatrutide, an experimental Eli Lilly drug that is available only inside its trials.
An official at SAHPRA, the country's medicines regulator, said the rules exist but enforcing them is hard.
Why it matters
Border officials say some medicines arrive declared as cosmetics, and they are looking at training dogs to sniff them out.
Why it matters
A Novo Nordisk manager said seeing sellers in the open can make buyers think the products are legal.
How it works
The ban on selling them is already written, but cases depend on prosecutors outside the regulator, so sellers advertise in the open.
The idea, in story 6: Why a banned medicine can be sold without the ban being lifted →What's really going on
In South Africa the rules against unapproved weight-loss jabs are already written, and the regulator says enforcing them is the hard part.
Why it works on people
A product on open sale, from a pharmacy or a social media seller, can look approved, so buyers may assume someone has checked it.
1 source
South Africa's drug firms ask for arrests over fake jabs
The full story
South Africa's drug firms ask for arrests over fake jabs
Drug industry leaders in South Africa called on Wednesday for seizures, arrests and prosecutions over weight-loss products sold without approval.
Why it matters. Border officials say some medicines arrive declared as cosmetics, and they are looking at training dogs to sniff them out.
4 in 10 US high school students binge eat
Swipe up for the story ↑Scroll down for the story ↓
About 40% of US high school students said they had binge eaten in the past month, in a large survey by the CDC, the US public health agency.
4 of 10
US high school students who binge ate in the past month
It is the first time the survey, which asks teenagers about risky behaviour, has asked about binge eating.
It defined it as eating an unusually large amount quickly while feeling unable to stop.
Why it matters
Binge eating was linked to checking social media at least every hour, poor mental health and suicidal thoughts.
Why it matters
Questions on eating had been dropped from the survey in 2015 to make room for questions on vaping.
1 source
4 in 10 US high school students binge eat
The full story
4 in 10 US high school students binge eat
About 40% of US high school students said they had binge eaten in the past month, in a large survey by the CDC, the US public health agency.
4 of 10
US high school students who binge ate in the past month
Why it matters. Binge eating was linked to checking social media at least every hour, poor mental health and suicidal thoughts.
A same-day test finds hidden infections in sick children
Swipe up for the story ↑Scroll down for the story ↓
Great Ormond Street Hospital, a children's hospital in London, used a same-day test on samples from 122 critically ill children.
The test reads all the genetic material in a sample, so doctors do not have to guess in advance which germ to look for.
It found about nine in ten bacteria and viruses, and all fungi.
In a quarter of cases the results changed a child's treatment, such as starting, stopping or switching an antibiotic.
Why it matters
It also found 50 germs that routine tests missed, and is being rolled out to about 30 intensive care units across the UK.
Why it matters
Stopping antibiotics that will not work helps slow germs becoming resistant to them.
Good news
A same-day test at Great Ormond Street Hospital in London changed the treatment of critically ill children in a quarter of cases. Willow Crowther, aged 10, recovered after it found a drug-resistant infection her first antibiotic could not treat.
1 source
A same-day test finds hidden infections in sick children
The full story
A same-day test finds hidden infections in sick children
Great Ormond Street Hospital, a children's hospital in London, used a same-day test on samples from 122 critically ill children.
Why it matters. It also found 50 germs that routine tests missed, and is being rolled out to about 30 intensive care units across the UK.
One brain shows what clearing amyloid may do
Swipe up for the story ↑Scroll down for the story ↓
Doctors at the University of Pennsylvania examined the brain of a man who took aducanumab, an Alzheimer's drug, in a trial.
The drug clears amyloid, a sticky protein that clumps between brain cells in Alzheimer's.
It had cleared amyloid from the ridges of his brain's surface but not from the grooves between them.
The cleared ridges had little tau, a second harmful protein, while the grooves had much more tau and more damage.
Why it matters
It is rare evidence from a human brain that removing amyloid may hold back tau.
Why it matters
But it is one man, so it cannot prove that the drug is why the two areas differ.
1 source
One brain shows what clearing amyloid may do
The full story
One brain shows what clearing amyloid may do
Doctors at the University of Pennsylvania examined the brain of a man who took aducanumab, an Alzheimer's drug, in a trial.
Why it matters. It is rare evidence from a human brain that removing amyloid may hold back tau.
AstraZeneca pays an AI firm to find drug targets
Swipe up for the story ↑Scroll down for the story ↓
AstraZeneca, the British-Swedish drugmaker, will pay insitro, an AI drug discovery company, $40 million up front to find new targets for medicines.
It could pay up to $1.46 billion more if the work passes set steps.
It will look at a fatty liver disease called MASH and at diseases of the heart muscle.
Why it matters
Gilead, Bristol Myers Squibb and Eli Lilly have all signed earlier deals with insitro.
Why it matters
Most of the money arrives only if the work succeeds, so the up-front payment is small next to the headline figure.
Who gains
insitro
It gets $40 million now from AstraZeneca to keep building its own drugs, with up to $1.46 billion more if the work succeeds.
1 source
AstraZeneca pays an AI firm to find drug targets
The full story
AstraZeneca pays an AI firm to find drug targets
AstraZeneca, the British-Swedish drugmaker, will pay insitro, an AI drug discovery company, $40 million up front to find new targets for medicines.
Why it matters. Gilead, Bristol Myers Squibb and Eli Lilly have all signed earlier deals with insitro.
Merck and Moderna choose where their cancer vaccine goes next
Swipe up for the story ↑Scroll down for the story ↓
Merck and Moderna are preparing to ask for approval of their personal mRNA cancer vaccine, used together with Merck's drug Keytruda.
In August they said it delayed melanoma, a skin cancer, coming back after surgery, in a large final-stage trial.
At the STAT Summit in Boston on Thursday, Moderna's president and Merck's research chief said they have focused on cancers where Keytruda already works well.
Small tests in pancreatic and stomach cancer are under way.
Why it matters
Each vaccine is built from up to 34 changed proteins in one patient's tumour, chosen by a computer program.
Why it matters
Moderna says data from several thousand trial patients could help improve that program.
1 source
Merck and Moderna choose where their cancer vaccine goes next
The full story
Merck and Moderna choose where their cancer vaccine goes next
Merck and Moderna are preparing to ask for approval of their personal mRNA cancer vaccine, used together with Merck's drug Keytruda.
Why it matters. Each vaccine is built from up to 34 changed proteins in one patient's tumour, chosen by a computer program.
US prosecutors offer a deal to firms that report fraud
Swipe up for the story ↑Scroll down for the story ↓
The US Justice Department is making it easier for health companies to report their own fraud, an official said at the STAT Summit on Thursday.
Companies will now report to one office at the department instead of a separate process at the US health department.
Firms that report misconduct can get benefits such as a cap on what they must pay.
Why it matters
Jacob Foster, who oversees the health fraud unit, said fraud steals from Medicare, the US health plan for older people, whose trust fund could run out.
How it works
The fraud law did not change; what changed is how hard prosecutors hit a firm that reports itself, with a cap on what it pays.
The idea, in story 6: Why a banned medicine can be sold without the ban being lifted →Who gains
Health firms that report their own fraud
The US Justice Department offers them a cap on what they pay, through a single office.
1 source
US prosecutors offer a deal to firms that report fraud
The full story
US prosecutors offer a deal to firms that report fraud
The US Justice Department is making it easier for health companies to report their own fraud, an official said at the STAT Summit on Thursday.
Why it matters. Jacob Foster, who oversees the health fraud unit, said fraud steals from Medicare, the US health plan for older people, whose trust fund could run out.
OrbiMed raises $3 billion, a third for Asia
Swipe up for the story ↑Scroll down for the story ↓
OrbiMed, a large health investment firm, has raised $3 billion for new funds in the US, Europe and Asia.
Its Asia fund raised over $1 billion, up from $751 million for the last one.
Fierce Biotech says interest in Asian biotech is rising because China has become a major source of new drugs for Western companies.
TCGX, another investor, raised $600 million for Asia earlier this month.
Why it matters
OrbiMed's managing partner, Carl Gordon, named China's rise as a biotech powerhouse as one reason to invest now.
Who gains
Asian biotech start-ups
OrbiMed's new Asia fund has over $1 billion to invest, up from $751 million last time.
1 source
OrbiMed raises $3 billion, a third for Asia
The full story
OrbiMed raises $3 billion, a third for Asia
OrbiMed, a large health investment firm, has raised $3 billion for new funds in the US, Europe and Asia.
Why it matters. OrbiMed's managing partner, Carl Gordon, named China's rise as a biotech powerhouse as one reason to invest now.
OMass raises $310 million in Oxford
Swipe up for the story ↑Scroll down for the story ↓
OMass Therapeutics, a drug start-up in Oxford, England, has raised $310 million.
Its lead drug, OMS1620, blocks the receptor for ACTH, a hormone that over-drives the adrenal glands in some people.
It is aimed at congenital adrenal hyperplasia, an inherited hormone disorder, and at Cushing's syndrome.
Why it matters
The drug has only reached the first single-dose stage of a safety trial in healthy volunteers.
Why it matters
Its backers include GV, the venture arm of Google's parent company, and the UK government's British Business Bank.
1 source
OMass raises $310 million in Oxford
The full story
OMass raises $310 million in Oxford
OMass Therapeutics, a drug start-up in Oxford, England, has raised $310 million.
Why it matters. The drug has only reached the first single-dose stage of a safety trial in healthy volunteers.
Galapagos's cell therapies sold to its ex-chief's start-up
Swipe up for the story ↑Scroll down for the story ↓
Lakefront Biotherapeutics, the Belgian company that used to be called Galapagos, has sold its unwanted cancer cell therapies.
The buyer, Armed Cell Therapeutics, is a Belgian start-up chaired by Paul Stoffels, a former Galapagos chief.
The deal includes two 'armed' CAR-T therapies, immune cells engineered to attack cancer, which are close to human testing.
Why it matters
Galapagos had offered the projects to big drugmakers and found no serious interest.
Who gains
Armed Cell Therapeutics
It gets Galapagos's cell therapy projects for 8 million euros up front, because no big drugmaker made a serious offer.
2 sources
Galapagos's cell therapies sold to its ex-chief's start-up
The full story
Galapagos's cell therapies sold to its ex-chief's start-up
Lakefront Biotherapeutics, the Belgian company that used to be called Galapagos, has sold its unwanted cancer cell therapies.
Why it matters. Galapagos had offered the projects to big drugmakers and found no serious interest.
How an Alzheimer's gene may strip nerve coating
Swipe up for the story ↑Scroll down for the story ↓
MIT scientists have found one way APOE4, the biggest inherited risk factor for late-onset Alzheimer's, may harm the brain's wiring.
Nerve fibres are wrapped in a fatty coat called myelin, made by helper cells.
In those helper cells, APOE4 turned down a chemical signal called Wnt, and fat piled up as droplets instead of becoming coating.
Restoring the signal brought the coating back in lab-grown cells and in mice.
Why it matters
It points to a possible target for drugs, but the evidence comes from cells and mice, not patients.
1 source
How an Alzheimer's gene may strip nerve coating
The full story
How an Alzheimer's gene may strip nerve coating
MIT scientists have found one way APOE4, the biggest inherited risk factor for late-onset Alzheimer's, may harm the brain's wiring.
Why it matters. It points to a possible target for drugs, but the evidence comes from cells and mice, not patients.
Eating late linked to liver disease
Swipe up for the story ↑Scroll down for the story ↓
People who often ate after dinner or after bedtime had a 20% to 30% higher risk of liver disease, in a study of nearly 200,000 people.
Researchers at Oregon Health and Science University used three long-running US studies of nurses and other health workers.
The liver runs on a daily body clock, which may be one reason.
Why it matters
It shows a link, not a cause, and people reported their own eating times.
Nobody knows yet
Whether eating late actually causes liver disease.
The study found a link in what people said about their own habits, which cannot show cause.
1 source
Eating late linked to liver disease
The full story
Eating late linked to liver disease
People who often ate after dinner or after bedtime had a 20% to 30% higher risk of liver disease, in a study of nearly 200,000 people.
Why it matters. It shows a link, not a cause, and people reported their own eating times.
Northern Ireland's hospital doctors to strike
Swipe up for the story ↑Scroll down for the story ↓
Hospital doctors in Northern Ireland will strike for 24 hours on 20 November and again on 23 November over pay.
Resident doctors, who are still training, strike first, then senior doctors.
Emergency care will continue, but most routine operations will be cancelled.
Why it matters
The Royal College of Nursing is also asking its members whether to strike.
1 source
Northern Ireland's hospital doctors to strike
The full story
Northern Ireland's hospital doctors to strike
Hospital doctors in Northern Ireland will strike for 24 hours on 20 November and again on 23 November over pay.
Why it matters. The Royal College of Nursing is also asking its members whether to strike.
MPs find endometriosis costs women their jobs
Swipe up for the story ↑Scroll down for the story ↓
A report by a group of UK MPs found 47% of women with endometriosis had lost income because of their symptoms, and 28% had left a job.
Endometriosis can cause severe pain, tiredness, heavy bleeding and trouble getting pregnant, and about one in ten women have it.
Fewer than half of employees with the condition had been given changes at work to help them.
Why it matters
One woman in the report paid about 6,000 pounds for private surgery because NHS waits were too long.
Why it matters
The UK health department says the condition is a priority in its women's health plan.
1 source
MPs find endometriosis costs women their jobs
The full story
MPs find endometriosis costs women their jobs
A report by a group of UK MPs found 47% of women with endometriosis had lost income because of their symptoms, and 28% had left a job.
Why it matters. One woman in the report paid about 6,000 pounds for private surgery because NHS waits were too long.
A US lawmaker wants faster early drug trials
Swipe up for the story ↑Scroll down for the story ↓
Jake Auchincloss, a Democratic member of the US Congress from Massachusetts, plans a bill to speed up early drug trials.
It would copy Australia, which lets early trials start without first being checked by its national regulator.
He told the STAT Summit on Thursday that the US cannot match China's low trial costs, but should match its speed.
He argued against trade barriers aimed at China's biotech industry.
Why it matters
Biotech is a big part of Massachusetts's economy, and the industry's investors share his view.
1 source
A US lawmaker wants faster early drug trials
The full story
A US lawmaker wants faster early drug trials
Jake Auchincloss, a Democratic member of the US Congress from Massachusetts, plans a bill to speed up early drug trials.
Why it matters. Biotech is a big part of Massachusetts's economy, and the industry's investors share his view.
That's the whole Biotech day.
26 stories, 29 sources.